SMMT Summit Therapeutics plc

-0.40  -3%
Previous Close 11.79
Open 11.87
Price To book 34.52
Market Cap 160181910
Shares 14,063,381
Volume 17,490
Short Ratio 0.33
Av. Daily Volume 51,948

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 primary endpoint of safety met - announced September 5, 2017. Phase 3 trial to be initiated 1H 2018.
C. difficile infection (CDI)
Phase 2 completion of initial dosing announced November 20, 2017. 24-week data due 1Q 2018.
Duchenne muscular dystrophy

Latest News

  1. Summit Completes Initial 24 Weeks of Dosing of Ezutromid in Patients With DMD in PhaseOut DMD Clinical Trial
  2. Summit Highlights Utrophin Modulation as a Potential Universal Treatment Option in DMD at 15th Action Duchenne International Conference
  3. Summit Announces Signing of Revenue Sharing Agreement With the Wellcome Trust for CDI Antibiotic Ridinilazole
  4. Grant of Share Options to Directors, PDMRs and Employees and Grant of Restricted Stock Units to Non-Executive Directors
  5. Summit Highlights Microbiome Preservation During Ridinilazole Treatment in Exploratory Phase 2 Clinical Trial at ID Week 2017
  6. Summit Highlights DMD Biomarker Validation Data and Phase 2 Clinical Trial Baseline Characteristics in Presentations at 22nd WMS Congress
  7. Summit Therapeutics to Host R&D Day 11 October 2017
  8. Summit Joins cTAP in Collaborative Effort to Enhance the Development of Utrophin Modulators and Other Treatments for Duchenne Muscular Dystrophy
  9. Summit Therapeutics Announces Exercise of Underwriters’ Over-Allotment Option
  10. Summit Therapeutics Announces Pricing of Public Offering of 1,459,000 American Depositary Shares
  11. Summit Therapeutics Announces Proposed Public Offering of $15.0 Million of American Depositary Shares
  12. Summit Awarded BARDA Contract Worth Up to $62 Million to Support the Development of Ridinilazole for the Treatment of C. difficile Infection
  13. Sarepta's Golodirsen Positive in DMD Study, Shares Soar
  14. Summit Therapeutics Plc :SMMT-US: Earnings Analysis: Q2, 2018 By the Numbers : September 6, 2017
  15. Summit Announces Positive Top-Line Data From an Exploratory Phase 2 Clinical Trial Supporting Ridinilazole as a Highly Selective Antibiotic for the Treatment of CDI
  16. Summit Therapeutics Reports Financial Results for the Second Quarter and Half Year Ended 31 July 2017 and Operational Progress
  17. Summit Therapeutics to Report Financial Results for the Second Quarter and Half Year Ended 31 July 2017 on 31 August 2017
  18. featured highlights: Summit Therapeutics, Commercial Vehicle Group, DragonWave, Townsquare Media and CONSOL Energy
  19. 5 Great Breakout Stocks Offering Excellent Returns